Illumina, Inc. ILMN

ILMN Company Overview

Illumina, Inc. is a publicly traded biotechnology company specializing in genomic sequencing and array-based technologies, operating primarily within the life sciences, biotechnology, and clinical diagnostics industries. The company’s core business is enabling the analysis of genetic variation and biological function, which supports research, clinical, and applied markets. Illumina’s offerings are widely used by academic institutions, pharmaceutical and biotechnology companies, clinical laboratories, and government organizations.

Illumina’s primary revenue drivers are the sale of next-generation sequencing (NGS) systems, consumables (such as reagents and flow cells), and informatics solutions, with consumables representing the largest and most recurring revenue stream. The company is uniquely positioned as a dominant provider of short-read sequencing technology, supported by a large installed base and high switching costs for customers. Founded in 1998, Illumina initially focused on array-based genotyping technologies and transitioned over time into sequencing, notably expanding its market leadership after acquiring Solexa, Inc. in 2007, which laid the foundation for its modern NGS platforms.